Do analysts rate CURX or VCNX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CURX or VCNX more profitable?

Vaccinex's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Curanex Pharmaceuticals N/A -82.07% -79.65% Vaccinex N/A N/A -383.58%

Do analysts recommend SNOA or VCNX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is RVPH or VCNX more profitable?

Vaccinex's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Reviva Pharmaceuticals N/A -391.58% -119.08% Vaccinex N/A N/A -383.58%

Do analysts rate VCNX or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, VCNX or GELS?

Gelteq has lower revenue, but higher earnings than Vaccinex. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaccinex $388K 5.03 -$20.25M -$48.27 N/A Gelteq $110K 86.97 -$4.30M N/A N/A

Is VCNX or GELS more profitable?

Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% Gelteq N/A N/A N/A

Do analysts prefer VCNX or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VCNX or ENVB more profitable?

Vaccinex's return on equity of 0.00% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% Enveric Biosciences N/A -168.04% -145.95%

Vaccinex (VCNX) Competitors

$0.75 -0.25 (-25.00%)

As of 09/3/2026 03:37 PM Eastern

Compare

VCNX vs. CURX, SNOA, RVPH, GELS, and ENVB

Should you buy Vaccinex stock or one of its competitors? Vaccinex's main competitors and comparable companies include Curanex Pharmaceuticals (CURX), Sonoma Pharmaceuticals (SNOA), Reviva Pharmaceuticals (RVPH), Gelteq (GELS), and Enveric Biosciences (ENVB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Vaccinex compare to Curanex Pharmaceuticals?

Curanex Pharmaceuticals (NASDAQ:CURX) and Vaccinex (NASDAQ:VCNX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Curanex Pharmaceuticals has higher earnings, but lower revenue than Vaccinex. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A
Vaccinex	$388K	5.03	-$20.25M	-$48.27	N/A

Vaccinex's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%
Vaccinex	N/A	N/A	-383.58%

In the previous week, Curanex Pharmaceuticals' average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
Curanex Pharmaceuticals	Neutral
Vaccinex	Neutral

50.1% of Vaccinex shares are owned by institutional investors. 39.7% of Curanex Pharmaceuticals shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Vaccinex beats Curanex Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Vaccinex compare to Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Vaccinex (NASDAQ:VCNX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Vaccinex has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Vaccinex's return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%
Vaccinex	N/A	N/A	-383.58%

In the previous week, Sonoma Pharmaceuticals' average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
Sonoma Pharmaceuticals	Neutral
Vaccinex	Neutral

Sonoma Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are held by company insiders. Comparatively, 51.5% of Vaccinex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sonoma Pharmaceuticals has higher revenue and earnings than Vaccinex. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$21.92M	0.29	-$3.17M	-$1.22	N/A
Vaccinex	$388K	5.03	-$20.25M	-$48.27	N/A

Summary

Sonoma Pharmaceuticals and Vaccinex tied by winning 6 of the 12 factors compared between the two stocks.

How does Vaccinex compare to Reviva Pharmaceuticals?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Vaccinex (NASDAQ:VCNX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Reviva Pharmaceuticals has higher earnings, but lower revenue than Vaccinex. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A
Vaccinex	$388K	5.03	-$20.25M	-$48.27	N/A

Reviva Pharmaceuticals presently has a consensus target price of $75.00, suggesting a potential upside of 13,788.89%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Reviva Pharmaceuticals is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Reviva Pharmaceuticals had 1 more articles in the media than Vaccinex. MarketBeat recorded 1 mentions for Reviva Pharmaceuticals and 0 mentions for Vaccinex. Reviva Pharmaceuticals' average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
Reviva Pharmaceuticals	Neutral
Vaccinex	Neutral

Vaccinex's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Vaccinex	N/A	N/A	-383.58%

Reviva Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

Summary

Reviva Pharmaceuticals beats Vaccinex on 8 of the 13 factors compared between the two stocks.

How does Vaccinex compare to Gelteq?

Vaccinex (NASDAQ:VCNX) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Gelteq has a beta of -0.41, suggesting that its stock price is 141% less volatile than the broader market.

In the previous week, Gelteq had 1 more articles in the media than Vaccinex. MarketBeat recorded 1 mentions for Gelteq and 0 mentions for Vaccinex. Vaccinex's average media sentiment score of 0.00 equaled Gelteq'saverage media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
Gelteq	Neutral

Gelteq has lower revenue, but higher earnings than Vaccinex.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	5.03	-$20.25M	-$48.27	N/A
Gelteq	$110K	86.97	-$4.30M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Gelteq	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

50.1% of Vaccinex shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Gelteq beats Vaccinex on 5 of the 9 factors compared between the two stocks.

How does Vaccinex compare to Enveric Biosciences?

Vaccinex (NASDAQ:VCNX) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Vaccinex's return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Enveric Biosciences	N/A	-168.04%	-145.95%

Enveric Biosciences has lower revenue, but higher earnings than Vaccinex. Enveric Biosciences is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	5.03	-$20.25M	-$48.27	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A

50.1% of Vaccinex shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 51.5% of Vaccinex shares are held by insiders. Comparatively, 2.4% of Enveric Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vaccinex has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

In the previous week, Vaccinex's average media sentiment score of 0.00 equaled Enveric Biosciences'average media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
Enveric Biosciences	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Vaccinex and Enveric Biosciences tied by winning 5 of the 10 factors compared between the two stocks.

Get Vaccinex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCNX vs. The Competition

Export

Metric	Vaccinex	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.95M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-0.02	787.27	273.29	25.25
Price / Sales	5.03	755.95	621.79	97.64
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	-0.29	12.31	13.08	6.14
Net Income	-$20.25M	$2.82B	$3.47B	$349.01M
7 Day Performance	-25.00%	2.59%	0.52%	-0.31%
1 Month Performance	-33.04%	6.95%	5.63%	0.64%
1 Year Performance	37.51%	9.44%	25.31%	14.83%

Vaccinex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCNX Vaccinex	N/A	$0.75 -25.0%	N/A	+37.5%	$1.95M	$388K	N/A	40	Gap Down
CURX Curanex Pharmaceuticals	0.2233 of 5 stars	$4.70 +2.2%	N/A	-96.1%	$7.38M	N/A	N/A	N/A	Gap Up
SNOA Sonoma Pharmaceuticals	0.3852 of 5 stars	$1.37 -1.1%	N/A	-71.4%	$6.54M	$19.53M	N/A	180
RVPH Reviva Pharmaceuticals	1.7629 of 5 stars	$0.48 -5.0%	$75.00 +15,525.0%	-94.1%	$6.29M	N/A	N/A	5	News Coverage Gap Down
GELS Gelteq	0.817 of 5 stars	$0.58 +0.0%	N/A	-20.3%	$6.21M	$165.65K	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCNX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaccinex (VCNX) Competitors

VCNX vs. CURX, SNOA, RVPH, GELS, and ENVB

How does Vaccinex compare to Curanex Pharmaceuticals?

Summary

How does Vaccinex compare to Sonoma Pharmaceuticals?

Summary

How does Vaccinex compare to Reviva Pharmaceuticals?

Summary

How does Vaccinex compare to Gelteq?

Summary

How does Vaccinex compare to Enveric Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaccinex (VCNX) Competitors

VCNX vs. CURX, SNOA, RVPH, GELS, and ENVB

How does Vaccinex compare to Curanex Pharmaceuticals?

Do analysts rate CURX or VCNX?

Which has higher valuation & earnings, CURX or VCNX?

Is CURX or VCNX more profitable?

Does the media refer more to CURX or VCNX?

Do insiders & institutionals believe in CURX or VCNX?

Summary

How does Vaccinex compare to Sonoma Pharmaceuticals?

Is SNOA or VCNX more profitable?

Does the media refer more to SNOA or VCNX?

Which has more volatility and risk, SNOA or VCNX?

Do analysts recommend SNOA or VCNX?

Do insiders & institutionals hold more shares of SNOA or VCNX?

Which has higher valuation and earnings, SNOA or VCNX?

Summary

How does Vaccinex compare to Reviva Pharmaceuticals?

Do institutionals and insiders hold more shares of RVPH or VCNX?

Which has higher earnings and valuation, RVPH or VCNX?

Do analysts prefer RVPH or VCNX?

Does the media favor RVPH or VCNX?

Is RVPH or VCNX more profitable?

Which has more volatility and risk, RVPH or VCNX?

Summary

How does Vaccinex compare to Gelteq?

Which has more volatility & risk, VCNX or GELS?

Does the media prefer VCNX or GELS?

Which has preferable earnings & valuation, VCNX or GELS?

Is VCNX or GELS more profitable?

Do analysts rate VCNX or GELS?

Do institutionals and insiders have more ownership in VCNX or GELS?

Summary

How does Vaccinex compare to Enveric Biosciences?

Is VCNX or ENVB more profitable?

Which has better valuation and earnings, VCNX or ENVB?

Do institutionals and insiders hold more shares of VCNX or ENVB?

Which has more risk and volatility, VCNX or ENVB?

Does the media prefer VCNX or ENVB?

Do analysts prefer VCNX or ENVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools